2 results
Approved WMOWill not start
PrimairTo determine the MTD and/or RP2D of oral twice daily (BID) BEZ235 in combination with trastuzumab in patients with HER2-positive breast cancerSecondairTo assess the preliminary activity of the combinationTo assess the safety and tolerability…
Approved WMORecruiting
This study investigates the correlation between IOS and the severity of fibrosis on HRCT in patients with IPF. It also investigates which IOS parameter best relates to the degree of fibrosis on the HRCT. Furthermore, as a secondary endpoint, it is…